Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430092 · ClinicalTrials.gov registry record · Phase 3
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
A Phase 3 study, sponsored by Sirion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT00430092 is a Phase 3 study that has completed, run by Sirion Therapeutics. The registered enrollment target is 219 participants.
The verdict
NCT00430092, a Phase 3 study, has completed, sponsored by Sirion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
Interventions
- DRUG Placebo
- DRUG Difluprednate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430092
The ClinicalTrials.gov registry entry for NCT00430092 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirion Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00430092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430092 about?
NCT00430092 is a clinical study titled "Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)". The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
What is the current status of trial NCT00430092?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants.
What interventions are being tested in trial NCT00430092?
The interventions under investigation include: Placebo (DRUG), Difluprednate (DRUG).
Who is sponsoring clinical trial NCT00430092?
This trial is sponsored by Sirion Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.